Abstract
Background and Objective
Concerns that antiepileptic brand-to-generic interchange results in disruption of seizure control are widespread. The objective of this study was to evaluate the safety and tolerability of the brand-to-generic levetiracetam switch in patients with focal or generalized epilepsy.
Methods
A prospective study in patients with primary, cryptogenic or symptomatic epilepsy, who were taking branded levetiracetam and were switched to generic levetiracetam. Patients were consecutively recruited from January 2013 to January 2015. We evaluated efficacy, tolerability and compliance before switching (T0) and after 6 months of therapy (T1). Evaluations were scheduled as follows: baseline, 7 and 15 days, 1, 3 and 6 months. At each visit clinical diary seizures, physical and neurological examination, laboratory parameters and electroencephalogram were evaluated.
Results
Fifty-nine patients, equally mixed by sex, were included in the study. Mean age was 26.1 years. Forty-seven per cent of the patients enrolled received levetiracetam as monotherapy. One patient was lost during the follow-up: so at T1 we had 58 patients (28 monotherapy and 30 polytherapy). At T0 and at T1, there was no statistically significant difference in terms of seizure frequency and intensity, occurrence of adverse events, laboratory parameters and electroencephalographic features. Two patients stopped treatment with the generic (both at 3 months after the switch) and restarted therapy with brand levetiracetam because of seizure increase. At the end of the study, the switchback rate was 3.4 %.
Conclusions
No increase of seizures and adverse effects were observed when branded levetiracetam was interchanged to a generic equivalent. More studies should be conducted with a larger series of patients to confirm these results.
References
Kesselheim SA, Stedman MR, Bubrick EJ, Gagne J, Misono A, Lee J, Bookhart A, Avorn J, Shrank W. Seizure outcome following use of generic vs. brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs. 2010;70:605–21.
Shaw SJ, Hartman AL. The controversy over generic antiepileptic drugs. J Pediatr Pharmacol Ther. 2010;15:81–93.
Liow K, Barkley GL, Pollard JR, Harden CL, Bazil CW. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology. 2007;68:1249–50.
Krauss GL, Caffo B, Chang YT, et al. Assessing the BE of generic AEDs. Ann Neurol. 2011;70:221–8.
Berg MJ, Gross RA, Tomaszewki KJ, et al. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology. 2008;71:520–30.
LeLorie J, Dhu MS, Paradis PE, Lefebvre P, Weiner J, Manjunath R, Sheehy O. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology. 2008;70:2179–86.
Chaisewikul R, Privitera MD, Hutton JL, Marson AG. Levetiracetam addon for drug-resistant localization-related (partial) Epilepsy (cochrane review). Cochrane Database Syst Rev. 2001;1:CD001901.
Krauss GL, Betts T, Abou-Khalil B, et al. Levetiracetam treatment of idiopathic generalized epilepsy. Seizure. 2003;12:617–20.
Louni C, Canevini MP, Capovila G, De Sarro G, Galimberti CA, Gatti G, Guerrini R, La Neve A, Mazzucchelli I, Rosati E, Specchio LM, Striano S, Tinuper P, Perucca E, Study of Outcome of PHarmacoresistence In Epilepsy (SOPHIE) collaborators. A prospective study of direct medical costs in a large cohort of consecutively enrolled patients with refractory epilepsy in Italy. Epilepsia. 2015;56:1162–73.
Ting TY, Jiang W, Lionberger R, Wong J, Jones JW, Kane MA, Krumholz A, Temple R, Polli JE. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: a field test of the FDA bioequivalence standard. Epilepsia. 2015. doi:10.1111/epi.13095 [Epub ahead of print].
Canevini MP, De Sarro G, Galimberti CA, Gatti G, Licchetta L, Malerba A, Muscas G, La Neve A, Striano P, Perucca E, SOPHIE Study Group. Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drud load in a large cohort of consecutive patients with drug-refractory epilepsy. Epilepsia. 2010;51:797–804.
Chaluvad S, Chiang S, Tran L, Goldsmith CE, Friedman D. Clinical experience with generic levetiracetam in people with epilepsy. Epilepsia. 2011;52:810–5.
Anderman F, Duh MS, Gosselin A, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia. 2007;48:464–9.
Abou-Khalil B. Levetiracetam in the treatment of epilepsy. Neuropsychiatr Dis Treat. 2008;4:507–23.
Fitzgerald CL, Jacobson MP. Generic substitution of levetiracetam resulting in increased incidence of breakthrough seizures. Ann Pharmacother. 2011;45(5):e27. doi:10.1345/aph.1P765 [Epub 2011 Apr 26].
Bautista RE, Gonzales W, Jain D. Factors associated with poor seizure control and increased side effects after switching to generic antiepileptic drugs. Epilepsy Res. 2011;95(1–2):158–67.
Erickson SC, Le L, Ramsey SD, Solow BK, Zakharyan A, Stockl KM, et al. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy. Epilepsia. 2011;52(7):1365–71.
Perucca E, Albani F, Capovilla G, et al. Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs. Epilepsia. 2006;47(Suppl 5):16–20.
French Chapter of the International League Against Epilepsy (LFCE). Recommendations on the use of generics for the treatment of epilepsy [cited 2009 September 18]. http://www.ilae-epilepsy.org. Accessed 18 Feb 2010.
Striano S, Striano P, Capone D, Pisani F. Limited place for plasma monitoring of new antiepileptic drugs in clinical practice. Med Sci Monit. 2008;14:173–8.
Hansen RN, Campbell JD, Sullivan SD. Association between antiepileptic drug switching and epilepsy-related events. Epilepsy Behav. 2009;15:481–5.
Bialer M, Midha KK. Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability. Epilepsia. 2010;51:941–50.
Margolese HC, Wolf Y, Desmarais JE, Beauclair L. Loss of response after switching from brand name to generic formulations: three cases and a discussion of key clinical considerations when switching. Int Clin Psychopharmacol. 2010;25:180–2.
Gagne JJ, Kesselheim AS, Choudhry NK, Polinski JM, Hutchins D, Matlin OS, Brennan TA, et al. Comparative effectiveness of generic versus brand-name antiepileptic medications. Epilepsy Behav. 2015;52(Pt A):14–8. doi:10.1016/j.yebeh.2015.08.014 [Epub ahead of print].
Italiano D, Bruno A, Santoro V, Lanza G, Muscatello MR, Zoccali R, Spina E. Generic olanzepine substitution in patients with schizophrenia: assessment of serum concentrations and therapeutic response after switching. Ther Drug Monit. 2015. doi:10.1097/FTD.0000000000000211.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No sources of funding were used to conduct this study.
Conflicts of interest
All authors declare no conflicts of interest that are relevant to the content of this study.
Ethical approval
The study was approved by Ethics Committee of the participating centers.
Informed consent
All patients provided written informed consent.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Vari, M.S., Pinto, F., Mencaroni, E. et al. Safety of Overnight Switch from Brand-Name to Generic Levetiracetam. Clin Drug Investig 36, 87–91 (2016). https://doi.org/10.1007/s40261-015-0351-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40261-015-0351-1